BioMarin Pharmaceutical received a price target upgrade to $97 from BMO Capital, reflecting about 50% upside from current levels. This follows positive Phase 3 trial results for VOXZOGO®, a treatment for hypochondroplasia, showing significant growth improvements in children. The company also strengthened its leadership by adding Dr. Robert Plenge, a top research executive from Bristol Myers Squibb, to its board. BioMarin has submitted a supplemental FDA application for VOXZOGO, aiming for approval and launch in 2027 as the first targeted therapy for this rare genetic condition.
BioMarin Pharmaceutical is the story's subject, here is Pluang's market snapshot as of Sep 16, 2026 00:52 WIB: Among 91 priced Health-sector US stocks on Pluang, 28 rose and 63 fell today. Notable movers include BNGO at USD 1.71 with a 28.57% increase, ASND at USD 231.16 down 12.74%, and ILMN at USD 225.13 up 8.13%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
Bitdeer reported mining 283.4 Bitcoin in the week ending October 23 and sold the entire amount. Their weekly update showed no net Bitcoin additions and zero holdings after excluding customer deposits. This follows a similar report from the previous w...
A leveraged long position of 315 Ether tied to 黄立成 showed a $21,000 unrealized loss, or 70%, as of October 24. The position used 25x leverage with an entry price of $2,447.57 and a liquidation price close at $2,336.90. Over the previous week, the add...
